Soligenix Inc. (NASDAQ:SNGX) Sees Large Decrease in Short Interest

Soligenix Inc. (NASDAQ:SNGX – Get Free Report) was the target of a large decline in short interest in October. As of October 30th, there was short interest totaling 66,373 shares, a decline of 59.3% from the October 15th total of 162,935 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily volume of 90,729 shares, the short-interest ratio is currently 0.7 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Soligenix in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Read Our Latest Stock Analysis on Soligenix

Soligenix Stock Down 8.7%

NASDAQ:SNGX traded down $0.03 during mid-day trading on Monday, reaching $0.29. The company’s stock had a trading volume of 223,761 shares, compared to its average volume of 2,289,809. Soligenix has a 1 year low of $0.28 and a 1 year high of $1.70. The stock has a fifty day moving average of $0.36 and a 200-day moving average of $0.64. The firm has a market capitalization of $6.85 million, a PE ratio of -0.65 and a beta of 2.04.

Soligenix (NASDAQ:SNGX – Get Free Report) last issued its earnings results on Friday, November 6th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.05. On average, analysts expect that Soligenix will post -0.55 earnings per share for the current year.

About Soligenix

(Get Free Report)

Soligenix, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare diseases and other serious medical conditions. Its work spans therapeutic programs for inflammatory and immunological disorders, as well as vaccine and medical countermeasure development. The company’s BioTherapeutics programs include HyBryte (SGX301), a topical treatment based on synthetic hypericin being developed for cutaneous T-cell lymphoma, and dusquetide (SGX942), which has been studied for oral mucositis associated with cancer treatment.

See Also

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.